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Abstract 
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency causes acute haemolytic anaemia trig-
gered by oxidative drugs such as primaquine (PQ), used for Plasmodium vivax malaria radical cure. However, in many 
endemic areas of vivax malaria, patients are treated with PQ without any evaluation of their G6PD status.
Methods: G6PD deficiency and its genetic heterogeneity were evaluated in northeastern and southeastern areas 
from Venezuela, Cajigal (Sucre state) and Sifontes (Bolívar state) municipalities, respectively. Blood samples from 664 
randomly recruited unrelated individuals were screened for G6PD activity by a quantitative method. Mutation analysis 
for exons 4–8 of G6PD gen was performed on DNA isolated from G6PD-deficient (G6PDd) subjects through PCR–RFLP 
and direct DNA sequencing.
Results: Quantitative biochemical characterization revealed that overall 24 (3.6 %) subjects were G6PDd (average 
G6PD enzyme activity 4.5 ± 1.2 U/g Hb, moderately deficient, class III), while DNA analysis showed one or two mutated 
alleles in 19 of them (79.2 %). The G6PD A-202A/376G variant was the only detected in 17 (70.8 %) individuals, 13 of them 
hemizygous males and four heterozygous females. Two males carried only the 376A → G mutation. No other muta-
tion was found in the analysed exons.
Conclusions: The G6PDd prevalence was as low as that one shown by nearby countries. This study contributes to 
the knowledge of the genetic background of Venezuelan population, especially of those living in malaria-endemic 
areas. Despite the high degree of genetic mixing described for Venezuelan population, a net predominance of the 
mild African G6PD A-202A/376G variant was observed among G6PDd subjects, suggesting a significant flow of G6PD 
genes from Africa to Americas, almost certainly introduced through African and/or Spanish immigrants during and 
after the colonization. The data suggest that 1:27 individuals of the studied population could be G6PDd and there-
fore at risk of haemolysis under precipitating factors. Information about PQ effect on G6PDd individuals carrying mild 
variant is limited, but since the regimen of 45 mg weekly dose for prevention of malaria relapse does not seem to be 
causing clinically significant haemolysis in people having the G6PD A-variant, a reasoned weighing of risk–benefit for 
its use in Venezuela should be done, when implementing public health strategies of control and elimination.
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Background
Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
is an erythro-enzymopathy, recessive and one of the 
most common X-linked hereditary genetic defects, due 
to mutations in the G6PD gene, which cause functional 
variants with many biochemical and clinical phenotypes, 
affecting about 400 million people worldwide [1, 2]. The 
related clinical manifestations range from haemolytic 
anaemia to favism, neonatal jaundice or rarely congeni-
tal non-spherocytic haemolytic anaemia [3, 4]. In general, 
an acute haemolytic attack can occur after taking certain 
oxidative drugs, such as primaquine (PQ), used in both 
the radical cure of Plasmodium vivax malaria and the 
presumptive anti-relapse therapy in people with exten-
sive exposure to P. vivax.
Although globally the estimated number of malaria 
cases decreased from 227 million in 2000 to 198 million 
in 2013, it remains the most important infectious dis-
ease in tropical and sub-tropical areas of the world [5]. 
Implementation of effective control, prevention, diagno-
sis, and treatment practices reduced by 47 % the malaria 
mortality rates worldwide between 2000 and 2013 in all 
age groups, 54 % in the WHO African Region and 53 % 
in children under 5-years of age. However, this dis-
ease caused 584,000 deaths worldwide (range 367,000–
755,000) during 2013 [5].
In the Americas, a substantial reduction (>75 %) in the 
incidence of microscopically confirmed malaria cases 
was reached in all endemic countries between 2000 and 
2013, with the exception of Guyana and Venezuela, for 
which a significant increase in malaria morbidity was 
described during the same period [5]. In Venezuela, 
371,473 malaria cases were recorded during the last dec-
ade, while vivax malaria accounted for 82 % of all cases, 
followed by Plasmodium falciparum (16 %), Plasmodium 
malariae (<1  %), and Plasmodium vivax/falciparum 
mixed (1.4 %) infections [6]. In this country the parasitic 
annual index amounted to 15.1/1000 inhabitants in 2014, 
showing an increase of 16 % in the last decade [7], Bolí-
var, Amazonas and Sucre states being among the Vene-
zuelan regions with higher malaria incidence (63.3, 16.9 
and 12.5 %, respectively) [6].
The elimination of reservoirs of infection and reduction 
of transmission rates are crucial tasks to the success of 
any malaria eradication programme [2, 8]. PQ treatment 
is currently the only licensed therapy active against the 
latent liver stages of P. vivax and the only drug with activ-
ity against the mature transmission stages of all Plasmo-
dium species [8, 9]. However, the main safety concern 
for PQ administration is the risk of acute haemolytic 
anaemia (AHA) in G6PD-deficient (G6PDd) individu-
als, who are uniquely vulnerable to oxidative stresses, as 
their erythrocytes do not have alternative pathways for 
G6PD-dependent, reduced nicotinamide adenine dinu-
cleotide phosphate (NADPH) production, essential to 
maintain their two main anti-oxidant defenses, reduced 
glutathione and catalase [10]. Tafenoquine, a most 
advanced product and putative successor of PQ that 
recently completed phase 2 clinical trials, has been con-
sidered to be used as a single-dose radical cure therapy 
against P. vivax, but the haemolytic risk with this long-
acting 8-aminoquinoline remains in force [11]. Intra-
vascular haemolysis caused by PQ can vary from mild 
to severe in G6PDd individuals, but the severity of this 
event seems to be related to PQ dosing and the variant of 
the G6PD enzyme [9, 11]. PQ should not be administered 
to patients with vivax malaria without previous evalua-
tion of their G6PD status. Haemolytic events associated 
with PQ use have been described in G6PDd individuals 
in LA and the Caribbean [12]. Increased risk for malaria-
related transfusions and death triggered by PQ-induced 
haemolysis were described in G6PDd subjects from Bra-
zilian Amazon, a region accounting for 99.8 % of the reg-
istered cases of malaria in Brazil [11]. One pediatric case 
of haemolysis was described in a traveler infected with 
malaria and treated with PQ, returning from an endemic 
area in Venezuela [13].
G6PD deficiency is still considered the most common 
of all clinically significant enzyme defects in human biol-
ogy [3]. G6PD deficiency prevalence depends on the 
region and ethnic group and it is highly prevalent in areas 
historically exposed to Plasmodium infections, in agree-
ment of selection by malaria [14], although it is more 
common in African and Asian than in European and 
American people [2]. A geostatistical model-based map 
has predicted an overall allele frequency of 8 % for G6PD 
deficiency, widespread across malaria-endemic regions, 
with lowest frequencies in the Americas and highest in 
sub-Saharan tropical Africa and Arabian Peninsula [2].
On the other hand, most of the countries of Latin Amer-
ica (LA) presenting cases of PQ-induced haemolysis 
show a higher prevalence of G6PDd when compared to 
other countries [12].
Over 400 different biochemical variants of G6PD have 
been described globally [10, 15, 16]. The G6PD locus 
shows a considerable degree of genetic heterogene-
ity and at least 186 distinct alleles involving mutations 
leading to single amino acid substitutions or deletions, 
scattered throughout the entire coding and non-coding 
region, have been identified [3, 15, 17]. Most of the vari-
ants occur sporadically, although some, such as the G6PD 
Mediterranean and the G6PD A-202A/376G variants, exist 
with an increased frequency in certain populations [18, 
19]. For example, G6PD A-202A/376G is distributed in rela-
tively homogeneous manner in Africa and the Americas. 
Although some studies carried out in regions of South 
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and Central America have previously shown heterogene-
ity of the G6PD variants [20–22], the G6PD A-202A/376G 
has been described as the genetic variant most broadly 
distributed across LA, present in 81.1 % of the deficient 
individuals surveyed [12]. This variant is due to a G → A 
transition at nucleotide position 202, which causes a 
Val → Met replacement at amino acid position 68 of the 
protein, that is carried in combination with a A → G sub-
stitution at nucleotide 376, corresponding to a change 
Asn → Asp at amino acid position 126. It determines a 
mild form of G6PD deficiency. Instead, the G6PD Medi-
terranean563T, a C → T substitution leading to an amino 
acid change Ser →  Phe at position 188, responsible for 
a severe form of G6PD deficiency, is widely distributed 
across southern Europe, the Middle East, through Iran, 
Afghanistan, Pakistan, and much of western India [2, 23]. 
However, more information is needed on the distribution 
of G6PD-deficiency variants in the world, as well as more 
affordable tests to identify at-risk individuals, particularly 
in malaria-endemic countries.
To date, limited studies have been undertaken to ascer-
tain the prevalence of G6PD deficiency in Venezuelan 
people [24–27]. One of them reported deficiency of 2 % 
in subject blood donors living in Caracas and 11.5–13.3 % 
in Afro-descendant people of Tapipa (Miranda state) [24]. 
Another study conducted in Bolívar state found 5.3 % of 
deficiency in individuals with suspected malaria [25]. But 
information about the molecular heterogeneity of the 
G6PD deficiency in Venezuela is not currently available.
In this study the prevalence rate of G6PD enzymatic 
activity was evaluated and the G6PD genetic variant 
identified in apparently healthy individuals from north-
eastern and southeastern regions of Venezuela to assess 
the rate and genetic basis of G6PD deficiency in endemic 
areas of vivax malaria.
Methods
Subjects and samples
Blood samples from 664 randomly recruited unrelated 
individuals were collected during the years 2005 and 
2006, of which 316 were females and 348 males. The 
sample represented all of those willing to do the screen-
ing and there was thus no bias in terms of gender (being 
females and males equally represented), age and ethnic 
origin. All of them were born in Venezuela, had a median 
age of 24 years (range 1–109 years), represented 1–2 % of 
the total population in the areas assessed and were living 
in two of the regions of Venezuela with high malaria inci-
dence: Sifontes municipality (332 individuals), located in 
the southeast of Bolívar state, near the lowland rain forest 
and savannas of Guayana, where the most of the popula-
tion (32.621 inhabitants) is exposed at high risk to malaria 
due to economic activities, such as agriculture, mining 
and forest exploitation, and Cajigal municipality, Sucre 
state (332 subjects), in the northeastern coastal plains, 
along the Caribbean Sea, largely composed of mangroves, 
herbaceous and woody swamps, where the population 
(18.942 inhabitants) lives mainly of fishing, subsistence 
agriculture, and tourism (Fig. 1). Both areas show annual 
mean temperature around 24–28  °C and rainfalls that 
are more directly influenced by the Atlantic inter-trop-
ical convergence zone. A written informed consent was 
obtained from each participant authorizing the collec-
tion of a 4-ml whole blood sample in ethylenediaminetet-
raacetic acid (EDTA) as anticoagulant, which was stored 
at 4  °C during the fieldwork, placed in liquid nitrogen 
within 24 h of collection and kept frozen until analysis.
Biochemical analysis of G6PD deficiency
The blood samples were screened for G6PD enzymatic 
activity using a quantitative method (NeoLISA G6PD 
assay, Interscientific® Corp, FL, USA) through the hae-
moglobin normalization procedure, following manufac-
turer’s instructions, and the values used to determine 
G6PD activity were expressed in U/g Hb (units per 
gram haemoglobin). The controls used were supplied by 
the manufacturer in three levels of G6PD activity (nor-
mal = 14.3 U/g Hb, intermediate = 4.7 U/g Hb and defi-
cient = 1.3 U/g Hb) at 37  °C, and the cut-off point was 
7.14 U/g Hb to define a subject as G6PDd on the basis 
of adjusted male median G6PD activity, as recommended 
by Domingo et  al. [28]. The rate of NADPH generation 
was spectrophotometrically measured at 570 nm (Titer-
tek Multiskan®, Phoenix Equipment Inc, USA). Samples 
of subjects with reduced activity were tested for G6PD 
gene mutations.
Molecular analysis of G6PD variants
Genomic DNA was extracted from G6PDd whole blood 
samples by using QIAamp DNA Blood Mini kit (Qia-
gen®, GmbH, Germany), according to manufacturer’s 
recommendations, and used as templates to search for 
the more common G6PD genetic variants whose muta-
tions are located within the exons 4–8 of G6PD gen. A 
polymerase chain reaction (PCR) using four pairs of 
previously described oligonucleotide primers [29, 30] 
and cycling conditions showed in Table  1, were applied 
to amplify the corresponding regions of exons 4–8 in a 
thermal cycler Eppendorf MasterCycler Personal (Eppen-
dorf, Hamburg, Germany). PCR products were analysed 
by agarose gel electrophoresis and ethidium bromide 
staining, and cleaved to perform the restriction frag-
ment length polymorphism (RFLP) analysis with 5 U 
of NlaIII, FokI and MboII endonucleases, in accord-
ance with procedures previously described [31, 32], and 
under conditions recommended by the manufacturer 
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(New England BioLab Inc, Beverly, MA, USA) to identify 
the 202G → A, 376A → G, 563C → T, and 844G → C 
substitutions (Table  1). Control DNA samples, carry-
ing the appropriate restriction site, were run along in 
each digestion set. Digested products were separated 
on 10  % polyacrylamide gel electrophoresis for 1  h at 
100  V and visualized by ethidium bromide staining. In 
addition, in order to search other nucleotide substitu-
tions located into the amplified exons (185C → A from 
exon 4, 542A → T, 592C → T, 593G → C, 634A → G, 
637G →  T and 680G →  A from exon 6/7, 820G →  A, 
835A → T, 854G → A and 871G → A from exon 8) and 
to confirm RFLP analysis results, all PCR products were 
further analysed by automated direct DNA sequencing in 
both directions using BigDye Terminator Cycle Chemis-
try (Macrogen® Inc, Korea).
Statistical analysis
Data were analysed for the comparisons of variables using 
2 × 2 tables with χ2 test, or Fisher’s exact test (two-tailed, 
95 % confidence intervals) when the size sample was less 
than 5 (Epi Info™ 7.1.4.0, CDC Atlanta, GA, USA). Mean, 
median (both stratified by gender), standard deviation 
and range of G6PD enzymatic activities were calculated 
to determine reference values in normal and deficient 
subjects. Student’s test was applied for comparisons of 




The biochemical characterization revealed that 24/664 
(3.6  %) subjects were G6PD-deficient as their G6PD 
activity level was less than 60  % of the adjusted male 
median value (Table 2). The overall prevalence of G6PD 
deficiency was higher in subjects from Cajigal (Sucre 
state) than from Sifontes municipality (Bolívar state) (6 
vs 1.2 %, p = 0.001), and the median age of the G6PDd 
subjects was 23 (±  21.5) years. Male to female ratio 
was approximately 2:1, but no statistically significant 
Fig. 1 Map of Venezuela showing both municipalities included in the study of prevalence of G6PD deficiency. People studied were living in two 
malaria endemic regions of Venezuela, Sifontes municipality, in the southeast of Bolívar state, and Cajigal municipality, in the northeastern coastal 
plains of Sucre state, along the Caribbean
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difference was observed (p = 0.11), being the G6PD defi-
ciency rate among males 4.7 % (n = 16/337) and among 
females 2.4 % (n = 8/327), considering 5 % standard error 
and 95 % confidential intervals (Table 2).
All G6PDd subjects detected were asymptomatic. The 
mean G6PD enzyme activity was of 4.5  ±  1.2 U/g Hb 
(ranging from 2.6 to 6.2 U/g Hb), significantly lower than 
that observed in normal subjects (12.9  ±  3.8 U/g Hb, 
p < 0.0001). This G6PD deficiency could be classified as 
moderately deficient enzyme, class III, according to the 
World Health Organization (WHO) criteria [31, 32]. A 
mean value of G6PD enzyme activity significantly higher 
was observed among G6PDd females than in males (5.5 
vs 4.1 %, p = 0.007).
Identification of G6PD gene variants in the deficient 
subjects identified
The PCR–RFLP analysis showed that 17 (70.8 %) out of 24 
G6PDd subjects with deficiency detected biochemically 
carried the mutated allele 202G → A and 19 (79.2 %) the 
Table 1 PCR/RFLP conditions used to identify the G6PD genetic variants of G6PDd unrelated individuals in the present 
study
RFLP restriction fragment length polymorphism analysis, bp base pairs, RE restriction endonuclease used for RFLP
a The remaining mutations located in the exons 4–8, specifically the 185C → A, 542A → T, 592C → T, 593G → C, 634A → G, 637G → T, 680G → A, 820G → A, 
835A → T, 854G → A and 871G → A, were studied by DNA sequencing
b Cycling conditions used in the PCR were as follows: 40 cycles at 94 °C for 1 min, 60 °C (for exon 4 and 8) or 56 °C (for exon 5) or 58 °C (for exon 6/7) for 30 s, and 72 °C 
for 40 s. A final elongation at 72 °C for 7 min was added
c Restriction endonuclease digestion carried out with 5 U of enzyme at 37 °C for 3 h
d NlaIII, FokI or MboII recognition site is created by the mutation
Mutations identified 
by PCR/RFLPa




References RFLP pattern (fragment size in bp)
REc Wild-type Mutantd




109 29 NlaIII 109 63, 46
376A → G 5 CAGTACGATGATGCAGC
CAGGTAGAAGAGGCGGT
90 FokI 90 58, 32
563C → T 6/7 ACTCCCCGAAGAGGGGT
CCAGCCTCCCAGGAGAGA
542 30 MboII 25, 26, 119,377 25, 26, 100, 119, 277
844G → C 8 GGAGCTAAGGCGAGCTC
CATGCTCTTGGGGACTG
230 NlaIII 11, 34, 75,110 11, 28, 47, 34,110
Table 2 Prevalence of  G6PD deficiency in  Venezuelan individuals from  Sifontes and  Cajigal municipalities and  G6PD 
gene alleles from subjects with biochemical deficiency
Data are in number (percentage) of cases for each condition
F females, M males, G6PDd G6PD-deficient subjects
# p = 0.001 by Fisher’s exact test for the comparison of G6PD deficiency prevalence among subjects of Cajigal vs. Sifontes municipality
* The biochemical test used was a NeoLiSA G6PD assay (Interscientific®, Hollywood, USA). p < 0.0001 by Student’s test for comparison of mean G6PD enzyme activity 
among normal and G6PDd subjects
** DNA analysis by PCR/RFLP and sequencing of the exons 4–8 of G6PD gene from subjects with biochemical deficiency. The other alleles, which were studied by 
sequencing (185C → A, 542A → T, 592C → T, 593G → C, 634A → G, 637G → T, 680G → A, 820G → A, 835A → T, 854G → A and 871G → A) resulted wild-type
a Mean G6PD enzyme activity of 12.9 ± 3.8 U/g Hb [defined as Class IV (in 84 %) and V (in 2 %) (data not shown)], according to WHO criteria (33, 34)
b Mean G6PD enzyme activity of 4.5 ± 1.2 U/g Hb (defined as moderately deficient enzyme, Class III, according to WHO criteria [33, 34]. p = 0.007 among G6PDd males 
and females compared by Student’s test
Geographical setting Gender TOTAL G6PD determination results
Biochemical test* DNA analysis(**)
Normal(a) G6PDd(#, b) Wild-type allele 202G → A allele 376A → G allele
Cajigal municipality (Sucre state) n = 332 F 163 156 (95.7) 7 (4.3) 3 4 4
M 169 156 (92.3) 13 (7.7) 1 11 12
Sifontes municipality (Bolívar state) n = 332 F 164 163 (99.4) 1 (0.6) 1 0 0
M 168 165 (98.2) 3 (1.8) 0 2 3
664 640 (96.4) 24 (3.6) 5 (20.8) 17 (70.8) 19 (79.2)
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substitution 376A → G. These results were all confirmed 
by DNA sequencing. No mutation was detected in five 
(20.8 %) out of 24 G6PDd subjects, as well as none of the 
additional mutations studied by DNA sequencing map-
ping into the exons 4–8. The information is summarized 
in Table 2.
The analysis showed that 17 (70.8 %) out of 24 subjects 
were carriers of both 202G → A and 376A → G mutated 
alleles, that define the G6PD A-variant of African origin. 
Thirteen (76.5 %) of them were hemizygous (males) and 
four (23.5  %) heterozygous (females) for each mutation. 
In addition, the 376A → G allele was detected in hemizy-
gosis in two males (Table 2).
Discussion
Malaria remains a global health problem. In Venezuela 
malaria is associated with socio-economic problems and 
failures in preventive measures and social protection 
actions. The wide distribution in the world of the G6PD 
deficiency further hampers malaria control efforts. Epi-
demiological studies to evaluate the distribution of this 
enzyme defect, particularly in regions with the highest 
risk of transmission of P. vivax, allowing implementa-
tion of PQ-based malaria radical cure programmes, as 
well as for the evaluation of new, more effective anti-
parasite drugs, potentially able to cause haemolysis, and 
of appropriate measures of tolerability and risk of severe 
adverse events, are needed. Moreover, the application of 
G6PD deficiency tests may dramatically increase the ben-
efits of PQ therapy by permitting the application of rela-
tively higher dose than the current standard regimen, and 
shortening treatment length.
There is currently no practical point-of-care field test 
for the detection of G6PDd subjects, so from a public 
health perspective uncertainty remains about the best 
procedures to follow. Studies of cost-effectiveness and 
budget impact for health services are recommended 
to support the incorporation of these tests into control 
programmes aimed at malaria elimination in endemic 
countries.
Because the haemolytic risk of PQ-based regimens in 
malaria-endemic regions depends also on the severity of 
G6PD mutations involved in the deficiency, G6PD genetic 
testing could be useful when the benefits of PQ treatment 
outweigh the risk in patients living in these areas. Moreo-
ver, G6PD biochemical tests could fail to detect a fraction 
of heterozygous subjects, although these have a bigger 
population of G6PD-normal erythrocytes, and therefore 
are unlikely to develop a serious haemolytic attack. The 
determination of the G6PD genetic variant allows more 
accurate prediction of the risk of haemolysis.
In this work the prevalence of G6PD deficiency was 
evaluated in subjects living in two of the most prevalent 
malaria regions of Venezuela, and for the first time the 
African G6PD A-202A/376G genetic variant involved in 
such enzyme deficiency was identified and confirmed at 
the molecular level as predominant.
The overall prevalence of G6PD deficiency (3.6  %) 
observed in the analysed Venezuelan population was 
low, although it was significantly higher in the sample 
from Sucre state than that from Bolívar state, which is 
probably due to higher prevalence of African hered-
ity in the north coastal area of Venezuela, as a result of 
slave immigration during colonial times [35]. This rate 
of G6PD deficiency is similar to that shown on a map 
modelling prevalence (>5  %) in Venezuela proposed by 
other authors [2]. The higher frequency of biochemical 
deficiency of G6PD observed in males than in females 
could be due to a skewed X-chromosome inactivation (or 
lyonization) in females, which determines the survival 
and growth of G6PD normal cells in G6PD heterozygous 
females, which could have been missed by the biochemi-
cal procedure but not by genetic testing.
The results obtained here suggest that 1:27 individu-
als of the studied population could be G6PDd and there-
fore at risk of haemolysis in the presence of precipitating 
factors. Low G6PDd subjects frequencies (<10  %) have 
been described in other LA countries, such as Argen-
tina, Bolivia, Mexico, Perú, and Uruguay, but higher in 
the Caribbean islands, Guianas, Pacific coastal regions of 
Colombia and Ecuador, and part of the Brazilian Atlantic 
coast, which are areas that received the greatest contribu-
tion of Africans during the slave trade [12, 23].
Two mutations were detected in most (71  %) of sub-
jects with biochemically determined deficiency, particu-
larly the 202G → A and the 376A → G, defining together 
the variant G6PD A-202A/376G, widely distributed in Africa 
where it seems to confer resistance to falciparum malaria 
[19, 36], and identified under other names in Spain, 
Mexico, Italy, and many other parts of the world [12, 37]. 
High prevalence of this G6PD variant has been reported 
in Brazil, Mexico, Cuba and Honduras [20–22, 38], but a 
great diversity of variants has been described and spread 
across American, European and Asian countries [12, 19, 
23]. Although in this study four regions were studied 
spanning five exons of the G6PD gene, which include the 
most common mutations described in G6PDd subjects 
of LA countries, it is not possible to exclude those muta-
tions located in other gene regions which can be involved 
in the deficiency. Even so, it is noteworthy the relatively 
homogeneous molecular base of the G6PD deficiency 
found in the analysed sample of Venezuelan population, 
contrasting with the high heterogeneity reported in sev-
eral studies that revealed a substantial number of G6PD 
variants in LA populations, such as the G6PD A-376G/968C, 
G6PD Santamaría376G/542T, G6PD Seattle844C, G6PD 
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Mediterranean563T, and G6PD Union1360T described in 
Mexico, Brazil and Cuba [20–22].
Although a systematic study from individuals living in 
other Venezuelan regions would be desirable to better 
understand the genetic background in the country, the 
presence of only two G6PD alleles, 202G →  A and the 
376A  →  G, in the people studied can be justified. The 
current Venezuelan population is the result of an intense 
racial admixture including diverse components, such as 
Amerindians, Europeans and Africans [35]. However, 
the mutated alleles 202G → A and the 376A → G may 
have been introduced in the country during the admix-
ture process predominantly by the African contribution, 
mainly from the sub-Saharan region, which occurred in 
the 16th, 17th and 18th centuries, the period when the 
slave trade was most active, but also later from the Carib-
bean islands [35, 39, 40]. As described by some authors, 
genetic heredity of African populations in Venezuela 
is basically concentrated in the African-derived towns, 
the entire coastal area of the country. Their geographic 
distribution was directly linked to the location of the 
agricultural plantations during the slave trade, and the 
distribution pattern of genes of the Colonial era reflect a 
very limited gene flow due to the isolation and endogamy 
typical of this population, with low or no mixture with 
Europeans, while the Amerindian lineages are almost 
non-existent [35]. Previous studies from different areas of 
this continent confirmed the virtual absence or a very low 
frequency of G6PDd subjects in Amerindian populations, 
including those of Amazonas state in Venezuela [12, 41, 
HA Pérez, pers comm]. Interestingly, G6PD A-202A/376G is 
the most common variant described among the Spanish 
population [37], and considering the important contribu-
tion that Spanish immigration had on the admixture pro-
cess in Venezuela, a significant gene flow from Africa to 
Europe and America through Spain cannot be excluded.
There has been considerable confusion about the drugs 
that are capable of producing haemolytic anaemia in 
patients with G6PD deficiency. The risk of serious harm 
in any given population exposed to PQ therapy remains 
a concern. Although a mild methaemoglobinaemia typi-
cally occurs with normal PQ dosing, it is probable that 
other precipitating factors, such as infections or treat-
ment with other drugs than PQ, can cause a slight short-
ening of the red cell lifespan in G6PDd patients and 
elicit a haemolytic episode. African A- has frequently 
been considered a variant associated with mild disease. 
In subjects carrying a G6PD A- variant, known to be a 
moderately deficient enzyme, the red cells retain more 
than 10  % of residual G6PD activity, mostly present in 
reticulocytes and younger erythrocytes [42]. As a conse-
quence of this residual activity, an acquired tolerance to 
daily PQ dosing can be developed in these patients, who 
are relatively resistant to PQ-induced haemolysis [43]. 
But contrary to current perception, the G6PD A- variant 
cannot be considered ‘mild’, because a significant haemo-
globin drop has been observed in studies with African 
patients using anti-malarial preparations containing dap-
sone [44] or after administration of a gametocytocidal 
drug combination containing PQ and an artemisinin, in 
40  % of children carrying the G6PD A- variant in Tan-
zania [45]. It cannot exclude that the A- variant may be 
involved in severe haemolytic crisis.
On the other hand, the current Food and Drug Admin-
istration (FDA)-approved PQ dose, to prevent relapse by 
P. vivax and P. ovale by killing liver stage hypnozoites, 
is 15  mg daily for 14  days (adult dose). This dose, used 
in combination with 25 mg of chloroquine, remains the 
recommended treatment for radical cure of adults with 
vivax malaria, and is implemented in Venezuela at pre-
sent. However, P. vivax strains acquired in some parts of 
the world require a higher dose of PQ to prevent relapse. 
To achieve reliable eradication of parasites, the CDC 
has recommended an increase in dose from 15 to 30 mg 
daily for 14 days for adults [46]; although expert opinion 
and clinical trial data support this recommendation, the 
30-mg daily dose is not FDA approved. More recently, 
a regimen of a 45-mg weekly dosing of PQ (adult dose) 
for eight weeks, which seems to be effective treatment 
against strains of P. vivax not killed by standard thera-
peutic regimens, has been recommended to treat indi-
viduals with a partial G6PD deficiency by a WHO expert 
committee [9, 19, 47, 48]. Although the data to support 
efficacy against malaria are limited, this dose has been 
associated with a limited and clinically apparent haemo-
lytic anaemia in moderately G6PD-deficient subjects 
[48], but these findings do not conclusively indicate that 
non-specific administration of PQ is safe. Currently there 
is still no international agreement on the frequency and 
type of G6PD deficiency, justifying the suspension of 
the use of PQ in the treatment of vivax malaria, but the 
implementation of drugs into malaria eradication pro-
grammes should go along with a more thorough assess-
ment of the clinical burden of G6PD condition in each 
region. Because Venezuela does not carry out the test 
for G6PDd before starting treatment with PQ, its use at 
higher doses should be applied only after a careful risk/
benefit assessment in a known G6PDd individual and 
under strict medical supervision.
Conclusion
The prevalence rate of G6PD deficiency was as low as 
that one shown by nearby countries, and the molecular 
base was relatively homogeneous. Understanding the 
G6PD deficiency and its diversity are key issues to analys-
ing evidence of PQ safety in malaria-endemic areas. This 
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is the first survey conducted to identify the genetic vari-
ant involved in G6PD deficiency in Venezuelan subjects, 
and it represents a contribution to the knowledge of the 
genetic structure of this population.
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